LabGenius has secured £35 million in Series B funding led by M Ventures to enhance its ML-driven drug discovery platform and advance its pipeline of multispecific antibodies.

Information on the Target

LabGenius is a pioneering drug discovery company based in London, specializing in the development of novel therapeutic antibodies through machine learning. Recently, the company successfully closed a £35 million Series B financing round, bringing its total funding to £58 million. The investment round was led by M Ventures, the corporate venture arm of Merck, and saw participation from new investors Octopus Ventures and LG Corp, alongside existing investors such as Atomico, Kindred Capital, Lux Capital, and Obvious Ventures.

LabGenius aims to enhance its proprietary machine learning (ML)-driven drug discovery platform known as EVA™, which is designed to rapidly identify unique and effective biotherapeutics. The investments will also enable LabGenius to advance a wholly-owned pipeline of multispecific antibodies targeted at treating solid tumors. By leveraging the capabilities of its platform, the company endeavors to forge strategic partnerships across diverse therapeutic modalities.

Industry Overview in the UK

The UK biotech sector has emerged as a global leader in innovation, supported by a strong ecosystem that includes leading academic institutions, a robust venture capital landscape, and government initiatives fostering biot